Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 3, 1999, Pages 319-323

  Thakur, C P ^a,b   Singh, R K ^a   Hassan, S M ^a   Kumar, R ^a   Narain, S ^a   Kumar, Ashok ^a  

^a Kala azar Research Centre   (India)

^b NONE   (India)

Author keywords

Adverse events; Amphotericin B; Chemotherapy; Cure rates; India; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CREATININE; HEMOGLOBIN; HYDROCORTISONE; STIBOGLUCONATE SODIUM;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRONCHOPNEUMONIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; FEVER; HEART FAILURE; HEART MUSCLE INJURY; HEMOGLOBIN DETERMINATION; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEURITIS; NIGHT BLINDNESS; PREGNANCY; RELAPSE; REST; RIGOR; SHIVERING; STOMATITIS; TREATMENT FAILURE; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

PROTOZOA;

EID: 0032804471     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90037-8     Document Type: Article

References (34)

1. Berman, J. D. & Wyler, D. J. (1980). An in vitro model for investigation of chemotherapeutic agents in Leishmania. Journal of Infectious Diseases, 142, 83-86.
2. Bolard, J. (1986). How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochimica et Biophysica Acta, 864, 257-304.
3. Brahmachari, U. N. (1941). Note on the history of the treatment of kala-azar with urea stibamine. Journal of Tropical Medicine and Hygiene, 44, 67-71.
4. Chia, J. & McManus, E. (1990). In vitro tumor necrosis factor induction assay for analysis of febrile toxicity with amphotericin B preparations. Antimicrobial Agents and Chemotherapy, 34, 906-908.
5. Durand, R., Paul, M., Pratlong, F., Rivollet, D., Dubreuil-Lemaire, M., Houin, R., Astier, A. & Deniau, M. (1998). Leishmania infantum: lack of parasite resistance to amphotericin B in clinically resistant visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 42, 2141-2143.
6. Gallis, H. A., Drew, R. & Pickard, W. W. (1990). Amphotericin B: 30 years of clinical experience. Review of Infectious Diseases, 12, 308-329.
7. Gigliotti, F., Shenep, J., Lott, L. & Thornton, D. (1987). Induction of prostaglandin synthesis as the mechanism responsible for chills and fever provided by infusion of amphotericin B. Journal of Infectious Diseases, 156, 784-789.
8. Giri, O. P. (1995). Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B [Reply]. Journal of Association of Physicians of India, 513, 306.
9. Grogle, N., Oduola, A. M. J., Cordero, L. D. C. & Kyle, D. E. (1989). Leishmania ssp.: development of Pentostam resistant clones in vitro by discontinuous drug exposure. Experimental Parasitology, 69, 78-90.
10. Grogle, M., Thomason, T. M. & Franke, E. D. (1992). Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene, 47, 117-176.
11. Hebeka, E. K. & Saloterovsky, M. (1965). Development of resistance to polyene antibiotics in Candida albicans. Journal of Bacteriology, 89, 1533-1539.
12. Jha, T. K. (1983). Evaluation of dimidine compound (pentamidine isethionate) in the treatment of resistant cases of kalaazar occurring in North Bihar, India. Transactions of the Royal Society of Tropical Medicine and Hygiene, 77, 167-170.
13. Jha, T. K., Giri, Y. N., Singh, T. K. & Jha, S. (1995). Use of amphotericin B in drug resistant cases of visceral leishmaniasis in North Bihar: India. American Journal of Tropical Medicine and Hygiene, 52, 536-538.
14. Levine, S. J., Walse, T. J., Martinez, A., Eichacher, P. Q., Lopez Berestein, G. & Natanson, C. (1991). Cardiopulmonary toxicity after liposomal amphotericin B infusion. Annals of Internal Medicine, 114, 664-666.
15. Mishra, M., Biswas, U. K., Jha, D. N. & Khan, A. B. (1992). Amphotericin versus pentamidine in antimony unresponsive kala-azar. Lancet, 340, 1256-1257.
16. Sunder, S. (1997). Treatment of visceral leishmaniasis, its current status. Journal of Association of Physicians of India, 45, 640-647.
17. Thakur, C. P. (1993). Diminishing effectiveness of currently used drug in the treatment of kala-azar and amphotericin B in antimony and pentamidine resistant kala-azar. In: Current Trends in Leishmania Research, Bhaduri, A. N., Basu, M. K., Sen, A. K. & Kumar, S. (editors). New Delhi: Council of Scientific and Industrial Research, pp. 234-262.
18. Thakur, C. P. (1995). Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. National Medical Journal of India, 8, 13-24.
19. Thakur, C. P. (1997). A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 668-670.
20. Thakur, C. P. (1998). Sodium antimony gluconate, amphotericin and myocardial damage. Lancet, 351, 1928.
21. Thakur, C. P., Kumar, M., Kumar, P., Mishra, B. N. & Pandey, A. K. (1988). Rationalisation of regimens of treatment of kalaazar with sodium stibogluconate in India: a randomised study. British Medical Journal, 296, 1557-1561.
22. Thakur, C. P., Kumar, M. & Pandey, A. K. (1991). Comparison of regimes of treatment of resistant kala-azar patients: a randomised study. American Journal of Tropical Medicine and Hygiene, 45, 435-440.
23. Thakur, C. P., Sinha, G. P., Pandey, A. K., Barat, D. & Sinha, P. K. (1993a). Amphotericin B in resistant kala-azar in Bihar. National Medical Journal of India, 6, 57-60.
24. Thakur, C. P., Sinha, G. P., Sharma, V., Pandey, A. K., Kumar, M. & Verma, B. B. (1993b). Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian Journal of Medical Research, 97, 170-175.
25. Thakur, C. P., Sinha, G. P., Sharma, V. & Barat, D. (1993c). The treatment of kala-azar during pregnancy. National Medical Journal of India, 6, 263-269.
26. Thakur, C. P., Sinha, G. P., Pandey, A. K., Barat, D. & Singh, R. K. (1994a). Daily versus alternate day regimen of amphotericin B in the treatment of kala-azar: a randomised comparison. Bulletin of the World Health Organization, 72, 931-936.
27. Thakur, C. P., Sinha, G. P., Barat, D. & Singh, R. K. (1994b). Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Annals of Tropical Medicine and Parasitology, 88, 365-376.
28. Thakur, C. P., Sinha, G. P., Barat, D. & Singh, R. K. (1995). Two-hour versus six-hour administration of amphotericin B in the treatment of kala-azar. International Journal of Antimicrobial Agents, 51, 115-117.
29. Thakur, C. P., Singh, G. P. & Pandey, A. K. (1996). Comparison of regimens of amphotericin B deoxycholate in kala-azar. Indian Journal of Medical Research, 103, 256-263.
30. Thakur, C. P., Sinha, G. P., Pandey, A. K., Kumar, N., Kumar, P., Hassan, S. M., Narain, S. & Roy, A. K. (1998). Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Annals of Tropical Medicine and Parasitology, 92, 561-569.
31. Wamock, D. (1991). Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy, 28, (supplement B), 27-28.
32. WHO (1982). Report on the informal meeting on chemotherapy of visceral leishmaniasis. Geneva: World Health Organization, TDR/Chem/Leish/V1/82.3.
33. WHO (1984). The Leishmaniases. Report of a Technical Committee. Geneva: World Health Organization, Technical Report Series, no. 701.
34. WHO (1990). Control of the Leishmaniases. Report of a Technical Committee. Geneva: World Health Organization, Technical Report Series, no. 793.